<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152343</url>
  </required_header>
  <id_info>
    <org_study_id>SF19108</org_study_id>
    <secondary_id>2R44CA189515</secondary_id>
    <nct_id>NCT04152343</nct_id>
  </id_info>
  <brief_title>An Intraoperative Guidance Platform for Radio Frequency Ablation</brief_title>
  <official_title>An Intraoperative Guidance Platform for Radio Frequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the hypothesis that use of the research RFA (Radiofrequency ablation)&#xD;
      Physics Library will result in more frequent technical success (complete necrotization of&#xD;
      target tissues) compared to ablations conducted without computer guidance.&#xD;
&#xD;
      The RFA Physics Library -- a Planning and Guidance Platform (PGP) (NE Scientific, LLC) --&#xD;
      will be used to support percutaneous liver RFA under CT-guidance by assisting physicians in&#xD;
      the identification of ablation targets, assessment of proper ablation probe placement, and&#xD;
      projection of the created ablation zones on the CT image.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Technical Success</measure>
    <time_frame>2 years post RFA treatment</time_frame>
    <description>Technical success is defined as the complete ablation of the target lesion (tumor and 3mm margin).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Local Occurrence</measure>
    <time_frame>2 years post RFA treatment</time_frame>
    <description>Local recurrence is defined as the detection of viable malignant tissues at a site which was previously treated by RFA.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>RFA Physics Library- PGP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The RFA Physics Library will be used during during percutaneous liver RFA procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RFA Physics Library -- a Planning and Guidance Platform (PGP)</intervention_name>
    <description>Research software used to support liver RFA of HCC lesions &gt;2cm</description>
    <arm_group_label>RFA Physics Library- PGP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. â‰¥ 18 years of age&#xD;
&#xD;
          2. Presence of hepatocellular carcinoma with a size equal or larger than 2cm.&#xD;
&#xD;
          3. Scheduled for CT-guided thermal ablation under General Anesthesia&#xD;
&#xD;
          4. Able to provide written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Absolute of relative contraindication to MRI:&#xD;
&#xD;
               1. the presence of an electronic implant, such as a pacemaker not approved for MRI&#xD;
&#xD;
               2. the presence of a metal implant, such as an aneurysm clip not approved for MRI&#xD;
&#xD;
               3. claustrophobia&#xD;
&#xD;
               4. the presence of other contraindication(s), such as inability to comfortably lie&#xD;
                  flat, history of working with metal, other implanted hardware or shrapnel&#xD;
&#xD;
          2. Target tumor adjacent to or within prior ablated or resected site.&#xD;
&#xD;
          3. Serious psychiatric illness not adequately controlled to permit patient cooperation to&#xD;
             obtain an MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric K Hoffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric K Hoffer, MD</last_name>
    <phone>603.650.7417</phone>
    <email>eric.k.hoffer@hitchcock.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric K. Hoffer, MD</last_name>
      <phone>603-650-7417</phone>
      <email>hoffer@hitchcock.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 2019</study_first_submitted>
  <study_first_submitted_qc>November 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Eric K. Hoffer</investigator_full_name>
    <investigator_title>Director, Vascular and Interventional Radiology</investigator_title>
  </responsible_party>
  <keyword>Radiofrequency Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

